| Literature DB >> 35324581 |
Halley Gora Ravuri1, Zainab Noor2, Paul C Mills1, Nana Satake1, Pawel Sadowski3.
Abstract
Mass spectrometry-based plasma proteomics offers a major advance for biomarker discovery in the veterinary field, which has traditionally been limited to quantification of a small number of proteins using biochemical assays. The development of foundational data and tools related to sequential window acquisition of all theoretical mass spectra (SWATH)-mass spectrometry has allowed for quantitative profiling of a significant number of plasma proteins in humans and several animal species. Enabling SWATH in dogs enhances human biomedical research as a model species, and significantly improves diagnostic and disease monitoring capability. In this study, a comprehensive peptide spectral library specific to canine plasma proteome was developed and evaluated using SWATH for protein quantification in non-depleted dog plasma. Specifically, plasma samples were subjected to various orthogonal fractionation and digestion techniques, and peptide fragmentation data corresponding to over 420 proteins was collected. Subsequently, a SWATH-based assay was introduced that leveraged the developed resource and that enabled reproducible quantification of 400 proteins in non-depleted plasma samples corresponding to various disease conditions. The ability to profile the abundance of such a significant number of plasma proteins using a single method in dogs has the potential to accelerate biomarker discovery studies in this species.Entities:
Keywords: Data Independent Acquisition; FASP; SWATH; dog; plasma proteomics
Year: 2022 PMID: 35324581 PMCID: PMC8953371 DOI: 10.3390/proteomes10010009
Source DB: PubMed Journal: Proteomes ISSN: 2227-7382
Samples used for generating peptide spectral library specific to dog blood plasma.
| No. | Condition | No. of Animals Used to Generate a Pooled Sample | Digestion Technique | Fractionation/Enrichment Technique |
|---|---|---|---|---|
| 1 | Healthy | 8 |
In-solution Filter-aided In-gel |
1D—SDS PAGE ProteoMiner enrichment Acetonitrile precipitation |
| 2 | Unhealthy (inflammatory and miscellaneous conditions) | 26 | Filter-aided | None |
Samples used for quantitative profiling of dog blood plasma proteins.
| No. | Condition | No. of Animals Used to Generate a Pooled Sample | Digestion | Fractionation/Enrichment Technique |
|---|---|---|---|---|
| 1 | Healthy | 8 | Filter-aided | None |
| 2 | Inflammatory conditions | 8 | Filter-aided | None |
| 3 | Miscellaneous conditions | 18 | Filter-aided | None |
Figure 1The Venn diagram represents the total number of identified proteins from plasma of healthy dogs after processing using different digestion techniques. Each digestion technique enabled the identification of different protein groups.
Figure 2The Venn diagram represents the comparison of a total number of proteins identified in plasma collected from healthy and unhealthy animals. A total of 132 proteins were overlapped between the conditions and 64 proteins were unique to unhealthy and 45 proteins were unique to healthy conditions.
Figure 3(A) SDS-PAGE of crude and ProteoMiner processed samples. Lane 1 = MW marker; Lane 2 = BSA; Lane 3 = crude dog plasma sample and Lane 4 = ProteoMiner treated healthy dog plasma sample. The arrows indicate the main difference in the protein band patterns and corresponding to depletion of albumin in the case of the treated sample. (B) Venn diagram represents the comparison of the total number of proteins identified in crude dog plasma and ProteoMiner processed plasma collected from healthy animals. ProteoMiner treatment enabled identification of the highest number of unique proteins (170) over a crude untreated plasma sample (46 unique proteins).
Figure 4(A) SDS-PAGE of supernatant and pellet fractions of ACN precipitated healthy dog plasma samples. Lane 1 = MW marker; Lane 2 = BSA; Lanes 3–6 = pellet fractions collected at pH 3.5, 5.0, 8.0 and 9.0, respectively; Lanes 7–10 = supernatant fractions collected at pH 3.5, 5.0, 8.0 and 9.0, respectively. (B) Bar diagrams showing the total number of identified proteins from plasma of healthy dogs in different fractions resulting from ACN precipitation and collected at different pH. Each bar represents an absolute number of protein groups identified in various fractions. At different pH, protein precipitation resulted in the identification of a similar number of proteins.
Figure 5Venn diagram showing the contribution of different fractionation techniques to proteins represented in a spectral library. Most of the proteins were overlapped between the techniques, however, the highest number of unique proteins (149) were identified in ProteoMiner fraction, followed by ACN precipitation (71 unique proteins) and least identified in SDS-PAGE (30 unique proteins).
Figure 6Characteristics of an assay to quantify 400 proteins in dog plasma. (A) Frequency plot of the number of peptides quantified per protein. (B) Violin plot of coefficient of variation (CV%) among technical replicates—confirming the consistency of peptide quantification among technical replicates. (C) Distribution of q-values for extracted peaks. (D) Distribution of mass errors for extracted product ions. (E) Logged peptides intensity from all technical replicates showing the reproducibility of peptide quantitation.
Figure 7Volcano plot demonstrating changes in proteins corresponding to (A) inflammatory condition and (B) miscellaneous disease conditions, when compared to healthy samples. The X-axis displays the magnitude of fold changes and the Y-axis shows the statistical significance. The horizontal line indicates the adjusted p-value cut-off of <0.05, and vertical lines denote the absolute log 2-fold change cut off of 0.5. The blue dots represent downregulated and the red dots represent upregulated proteins in different clinical conditions.
List of proteins present in the current generated spectral library and their involvement in different diseases of dogs.
| Sl. No. | Disease Condition | Proteins Studied | Reference |
|---|---|---|---|
| 1 | Canine Babesiosis | Alpha 1 acid glycoprotein, Apolipoprotein A-1, Complement c3, Hemopexin, Alpha 2-HS glycoprotein, Haptoglobin, Clusterin | [ |
| 2 | Canine lymphoma | Apolipoprotein A-I, Apolipoprotein C-I, Apolipoprotein C-II, Apolipoprotein C-III, Apolipoprotein E, Beta-2-glycoprotein 1, Clusterin, Coagulation factor IX, Fibrinogen alpha chain, Fibrinogen beta chain (Fragment), | [ |
| 4 | Canine Pyometra | Alpha-1-acid glycoprotein 1, Haptoglobin, Alpha-2-macroglobulin, Hemopexin, Transthyretin, Transferrin receptor protein, Retinol-binding protein, Gelsolin, Alpha 2-HS glycoprotein | [ |
| 5 | Canine Mammary tumors | Alpha-1-microglobulin/bikunin precursor, Angiotensinogen, Serum albumin, Gelsolin | [ |
| 6 | Canine Chronic Valve disease | Apolipoprotein B, Apolipoprotein M, Apolipoprotein D | [ |
| 7 | H3N2 canine Influenza virus | Haptoglobin, Apolipoprotein E, Alpha 1 acid glycoprotein, Beta-2-microglobulin | [ |
| 8 | Duchenne muscular dystrophy | Alpha-1-B glycoprotein, Alpha 2-HS glycoprotein, Fetuin B, Hemopexin, Tropomyosin 2 | [ |
| 10 | Canine Encephalitis | Hemopexin, Gelsolin, Transthyretin, Beta-2-glycoprotein 1 Apolipoprotein E | [ |
| 11 | Canine Leishmaniasis | Haptoglobin, Hepatocyte growth factor activator, Hyaluronan binding protein 2 | [ |
List of proteins identified as biomarkers of different human diseases present in current dog spectral library.
| Sl. No. | Protein Name | Human Disease Condition | Reference |
|---|---|---|---|
| 1 | Gelsolin | Glioma | [ |
| 2 | Ceruloplasmin | Identified as a protein biomarker in prostate cancer | [ |
| 3 | Haptoglobin | Identified as biomarker in lung adeno carcinoma | [ |
| 4 | Alpha 1 antitrypsin | Studied in human breast cancer | [ |
| 5 | Vimentin | Expressed in human and canine osteosarcoma cells | [ |
| 6 | Tropomyosin 3 | Upregulated in metastatic carcinomas | [ |
| 7 | Myosin light chain 2 | Downregulated in metastatic mammary carcinoma, which is also expressed in human breast cancer | |
| 9 | Triosephosphate isomerase | Analysed as autoantigens from the canine mammary cell line | [ |
| 10 | Transthyretin | Identified as biomarkers for detecting early stage of ovarian cancer in human | [ |
| 12 | Tissue inhibitor of metalloproteinase 1 (Fragment) | Pancreatic cancer | [ |
| 13 | Alpha 2-HS glycoprotein Transthyretin | Colorectal cancer | [ |